In bid to enhance outcomes for youngsters with genetic bone illness, Swedish startup BOOST Pharma raises further €3.1 million

Stockholm-based BOOST Pharma, a clinical-stage biopharmaceutical firm targeted on growing novel cell therapies for uncommon skeletal pediatric ailments, as we speak introduced that Sound Bioventures has joined its investor syndicate with a €3.1 million funding.

The financing will help continued scientific growth of BT-101, BOOST Pharma’s pioneering stem cell-based remedy for osteogenesis imperfecta (OI), also referred to as brittle bone illness.

“We’re honored to welcome Sound Bioventures to our syndicate – a collaborative, hands-on investor group that shares our imaginative and prescient of remodeling care for youngsters residing with uncommon skeletal ailments,” mentioned Ingelise Saunders, Chair of BOOST Pharma. “Their dedication strengthens BOOST Pharma’s place as a pacesetter in cell remedy for genetic bone problems and allows continued progress of BT-101 in the direction of the clinic.”

This funding into BOOST Pharma displays a wider sample of European funding for superior cell- and gene-therapy ventures in 2025.

In Sweden, Cellcolabs raised €10.3 million to scale manufacturing of mesenchymal stem cells, aiming to cut back manufacturing prices and broaden entry to regenerative therapies. In Germany, Akribion Therapeutics secured €8 million for its programmable cell-depletion platform, whereas Finland’s StemSight attracted €2.3 million to progress stem-cell therapies for restoring imaginative and prescient. In neighbouring Denmark, Fuse Vectors closed €4.9 million to develop its cell-free viral vector expertise supporting gene-therapy supply.

With each BOOST Pharma and Cellcolabs headquartered in Sweden, the nation reveals a rising focus of regenerative-medicine innovation, reinforcing Sweden’s and Europe’s broader dedication to clinical-stage biotech growth.

“We consider BOOST Pharma’s modern method to treating osteogenesis imperfecta has huge potential to ship not solely scientific impression for sufferers but in addition sturdy worth creation. We sit up for working collectively to achieve new milestones,” mentioned Johan Kördel, Managing Associate at Sound Bioventures.

Based in 2019, BOOST Pharma is predicated on years of collaborative analysis from Karolinska Institute in Stockholm with the concentrate on novel cell remedy therapies for Osteogenesis Imperfecta. The analysis groups of affiliate professor Cecilia Götherström and professor Magnus Westgren have reportedly proven that that therapy with BOOST Cells enormously enhanced the standard of life for sufferers affected by this in any other case extraordinarily debilitating illness.

BOOST Pharma has made important progress advancing BT-101, a novel mesenchymal stem cell remedy supposed for youngsters born with OI. BT-101 is designed for early intervention, administered to infants to deal with the underlying reason for OI and cut back fracture frequency in affected youngsters.

In mice fashions, BT-101 has proven that cell remedy results in increased calcium deposition, increased alkaline phosphatase exercise, and a excessive ectopic bone formation.

As soon as injected, cells will migrate to the bone of sufferers with OI, the place they may engraft and begin bone formation. BOOST Pharma obtained human proof-of-concept for BT-101 after 4 youngsters with Kind III and IV OI had been handled; the youngsters have been adopted for years as much as adolescence.

BT-101 allegedly reveals nice promise for the effectiveness of treating youngsters with OI: the youngsters handled adopted their very own progress curve, had elevated lengthwise progress in comparison with up to date OI sufferers and confirmed a major discount of bone fractures. The cells are thought of to be protected with no hostile reactions and no immune responses in the direction of the donor MSC.

BT-101 remedy begins on the prenatal stage, when OI is first identified, or as early as attainable after the kid is born. By treating this early, BOOST Pharma is addressing the illness on the earliest attainable stage, thereby rising the therapy advantages for the affected person in later years, comparable to sturdy bones and presumably improved lung operate.

With this new funding, BOOST Pharma goals to speed up scientific growth and transfer nearer to delivering the primary disease-modifying remedy for OI.